https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Atara_Biotherapeutics%2C_Inc.Atara Biotherapeutics, Inc. - Revizia istoricului2026-04-12T22:15:19ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Atara_Biotherapeutics,_Inc.&diff=407855&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Atara Biotherapeutics, Inc. listata cu simbolul US.ATRA ==Descriere companie== Atara Biotherapeutics, Inc. (www.atarabio.com) is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (ta...2024-09-18T13:39:55Z<p>Pagină nouă: Pagina dedicata companiei Atara Biotherapeutics, Inc. listata cu simbolul US.ATRA ==Descriere companie== Atara Biotherapeutics, Inc. (www.atarabio.com) is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (ta...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Atara Biotherapeutics, Inc. listata cu simbolul US.ATRA<br />
<br />
==Descriere companie==<br />
Atara Biotherapeutics, Inc. (www.atarabio.com) is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. The Company’s ATA188 is a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. Its ATA2271 is an autologous chimeric antigen receptors (CAR) T immunotherapy targeting solid tumors expressing the tumor antigen mesothelin.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ATRA" /><br />
<br />
==Ultimele stiri despre Atara Biotherapeutics, Inc. (US.ATRA)==<br />
<dynamicpagelist><br />
category=US.ATRA<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ATRA]][[Categorie:Stiri despre companii]]</div>Admin